Get started
Author

Susan E. Gueble

Observed names: S.E. Gueble, Susan E Gueble, Susan Gueble, Susan E Gueble
Institution: Yale University
ORCID: 0000-0002-8043-1147
Observed ORCID: 0000-0002-8043-1147
OpenAlex ID: A5087388392
Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
2019 · Alanna R. Kaplan, Susan E. Gueble, et al. · Science Translational Medicine · 157
Mechanism-based design of agents that selectively target drug-resistant glioma
2022 · Kingson Lin, Susan E. Gueble, et al. · Science · 121
The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma
2024 · Matthew McCord, Thomas Sears, et al. · Neuro-Oncology · 11
PDF
DNA repair helicases: from mechanistic understanding to therapeutic implications
2025 · Vijay Menon, Susan E Gueble · NAR Cancer · 10
Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
2024 · Eric D. Huseman, Anna Lo, et al. · Journal of the American Chemical Society · 10
PDF
Oncometabolites as Regulators of DNA Damage Response and Repair
2021 · Susan E. Gueble, Ranjit S. Bindra · Seminars in Radiation Oncology · 7
The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors
2022 · Susan E. Gueble, Juan C. Vasquez, et al. · Current Treatment Options in Oncology · 6
Novel Strategies for Improved Treatment of O6-Methylguanine-DNA Methyltransferase Promoter-Methylated Glioma
2025 · Juan C. Vasquez, Ranjit S. Bindra, et al. · Medical Research Archives · 4
PDF
Targeted CRISPR knockout screening identifies known and novel chemogenomic interactions between DNA damaging agents and DNA repair genes
2025 · Collin D Heer, James L Elia, et al. · NAR Cancer · 2
DNA damage response profile distinguishes poor-acting gliomas with shared methylome signatures
2025 · Nalin Leelatian, Charu Singh, et al. · Neuro-Oncology · 1
PDF
Development of Syngeneic Murine Glioma Models with Somatic Mismatch Repair Deficiency to Study Therapeutic Responses to Alkylating Agents and Immunotherapy
2025 · Deepti Bhatt, Ranjini K. Sundaram, et al. · Current Protocols · 1
PDF
Mechanism of Action of KL-50, a Novel Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
2023 · Eric Huseman, Anna Lo, et al. · ChemRxiv · 1
PDF
Abstract 1568: Mechanistic studies of KL-50, a novel imidazotetrazine for the treatment of MGMT-/MMR- gliomas and glioblastoma
2023 · Eric D. Huseman, Anna Lo, et al. · Cancer Research · 1
Combining interstrand crosslinking agents with histone deacetylase inhibitors against high grade IDH mutant gliomas
2026 · Thomas K. Sears, Lillian Coe, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Targeting O6-methylguanine-DNA Methyltransferase Deficiency in Preclinical Models of Extracranial Human Cancers with a Tumor-Selective DNA-Modifying Agent
2026 · Ranjini K. Sundaram, Spenser S. Johnson, et al. · Molecular Cancer Therapeutics
PDF
Biomarker-Targeted O 6 -Guanine Alkylation Potentiates ATR Inhibitor Response in De Novo and Relapsed/Refractory AML
2026 · Prateek Bhardwaj, Amro Baassiri, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Abstract A060: Targeting metabolic–DNA repair vulnerabilities in SDHB- and FH-deficient renal cell carcinoma with the novel alkylating agent KL-50
2026 · Suparna M. Basu, Ranjini Sundaram, et al. · Clinical Cancer Research
MGMT-silencing as a novel biomarker in AML: Rational application of a dual alkylator-DNA crosslinker for targeted therapy
2025 · Prateek Bhardwaj, Amro Baassiri, et al. · Blood
PDF
EXTH-105. Comparative analysis of the MGMT-sensitive interstrand crosslinking agent KL50 based on IDH status in MMR-proficient and -deficient gliomas
2025 · Thomas Sears, Rahul Chaliparambil, et al. · Neuro-Oncology
PDF
Clinical outcomes following brachytherapy for endometrial cancer patients with narrow vaginal anatomy
2025 · Bethel Adefres, Christopher J. Tien, et al. · Brachytherapy
Abstract 2902: Systematic mapping of chemo-genomic interactions between DNA damaging agents and DNA damage repair genes with targeted CRISPR knockout screening
2025 · Collin D. Heer, Spenser S. Johnson, et al. · Cancer Research
O6-Guanine Targeting Novel DNA Cross-Linker and ATR Inhibitor Combination for MGMT-Silenced IDH1/2 Mutant Acute Myeloid Leukemia
2024 · Prateek Bhardwaj, Ranjini Sundaram, et al. · Blood
PDF
712 Modeling response to alkylating chemotherapy in a syngeneic model of MMR-deficient glioma
2024 · Deepti Bhatt, Ranjini K Sundaram, et al. · Regular and Young Investigator Award Abstracts
Dosimetric Analysis of Stereotactic vs. Intensity-Modulated Radiation Therapy for Pancreatic Cancer
2024 · P. Oh, J.H. Laird, et al. · International Journal of Radiation Oncology*Biology*Physics
PDF
Abstract 7123: Biomarker-targeted alkylator and DNA damage repair inhibitor combination for refractory and relapsed acute myeloid leukemia (AML)
2024 · Prateek Bhardwaj, Ranjini Sundaram, et al. · Cancer Research
Works count: 26
Citation count: 332
H-index: 6
I10-index: 5
Year
Topic
Type